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Abstract
Sinonasal cancers are rare tumors constitute 3% of head and neck cancers. These include
malignancies of the nasal cavity and paranasal sinuses (maxillary sinus, ethmoid sinuses,
frontal sinus and sphenoid sinus). Patients are often asymptomatic until late in the course
of their disease. Tumors of the maxillary sinus are more common than those of the
ethmoid sinus or nasal cavity. The workup for patients with suspected paranasal sinus
tumors includes complete head and neck CT/MRI with contrast. FDG-PET/CT may be
considered in the workup of patients with clinically apparent stage III or IV disease. The
most common histology for these tumors is squamous cell carcinoma, others reported
includes adenocarcinoma, esthesioneuroblastoma, minor salivary gland tumors, or
sinonasal neuroendocrine carcinoma [SNEC]). Surgical resection for all T stages (except
T4b, any N) followed by postoperative therapy remains a cornerstone of treatment. How-
ever, definitive RT or systemic therapy/RT is recommended for T4b, any N. Locoregional
control and incidence of distant metastasis are dependent on T stage, N stage, and tumor
histology.
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1. Introduction
Para-nasal sinuses are small air filled cavities occupying the facial and skull bones and along
with nasal cavity, they form a small anatomical space but they are site of origin of histologi-
cally diverse group of tumors. These incorporate neoplasms derived from mucosal epithelium,
seromucinous glands, soft tissues, bone, cartilage, neural/neuroectodermal tissue, haemato-
lymphoid cells and the odontogenic apparatus.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Epidemiology
Nasal cavity and paranasal sinus cancers are a group of rare cancers, representing about 5% of
all head and neck (H and N) cancer patients. They have an incidence of about 1 case every
100,000, with an average age between 50 and 60 years [1]. About 60% of sinonasal tumors
originate in the maxillary sinus, 20–30% in the nasal cavity, 10–15% in the ethmoid sinus, and
1% in the sphenoid and frontal sinuses [2]. The incidence of cancer of the nasal cavity and
paranasal sinuses (sinonasal cancer) is low in most of the populations (<1.5/100,000 in men
and <1.0/100,000 in women), although higher incidence is seen in Japan and certain parts of
China and India [3, 4]. Sinonasal squamous cell carcinoma and intestinal-type adenocarcinoma
occur more commonly in men, with a male-to-female ratio of 2:1 in sinonasal squamous cell
carcinoma, and up to 6:1 in intestinal-type adenocarcinoma [4, 5].
3. Anatomy
The paranasal sinuses are named according to the bones in which they are located: the
ethmoid, maxilla, sphenoid, and frontal (Figure 1) [6].
3.1. Ethmoid complex
This paired complex of sinuses contains 3–18 cells that are grouped as anterior, middle, or
posterior, according to the location of their ostia. The posterior group drains into the superior
meatus above the middle nasal concha; sometimes one or more opens into the sphenoidal
Figure 1. A schematic illustration of the relationship between the eye and the paranasal sinuses. The roof of the orbit, the
medial wall, and the floor are shared by the frontal, ethmoid, and maxillary sinuses, respectively.
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sinus. The middle group into the middle meatus of the nose on or above the bulla ethmoidalis
and the anterior group drains into the middle meatus of the nose by way of the infundibulum.
Since ethmoid sinus is a paired structure, it is connected in midline by cribriform part of
ethmoid bone, which also separates it from anterior cranial fossa. Direct extension of the tumor
through cribriform plate causes involvement of frontal lobe. A pointed bony landmark called
crista galli stretches out from the midline of the cribriform plate upward into the floor of the
anterior cranial fossa. The perpendicular plate of the ethmoid bone descends from the cribri-
form plate forms superior two thirds of the nasal septum. Middle, superior, and supreme
turbinates originate from medial wall of each ethmoid labyrinth. Lamina papyracea forms the
thin lateral wall, separating the ethmoid cells from the orbit. It forms an easy conduit for tumor
spread from ethmoid sinus to orbit. The fovea ethmoidalis is a segment of the ethmoid bone
and represents its superior portion which is seen as a continuation of the superior orbital roof
to the cribriform plate.
3.2. Maxillary sinus
The maxillary sinus is the largest sinus occupying the body of the maxillary bone. The sinus is
pyramidal in shape and has three recesses. The alveolar recess lies inferiorly, the zygomatic
recess pointing laterally and the infra-orbital recess pointing superiorly. The floor is formed by
the alveolar process of the maxilla. The roof is formed by floor of the orbit. It is traversed by
infraorbital nerves and vessels. The base of the maxillary sinus forms the inferior part of the
lateral wall of the nasal cavity. Anterior wall of the pterygopalatine fossa, also known as the
sphenopalatine fossa, forms posterior wall of the maxillary sinus. The anterior sinus wall is
the facial surface of the maxilla that is perforated by the infraorbital foramen below the orbital
rim. The maxillary sinus drains into the middle meatus by means of the semilunar hiatus. The
floor of the maxillary sinus is slightly below the level of the nasal cavity, and it is related to the
upper teeth [7].
3.3. Sphenoid sinus
Sphenoid sinus is a paired structure that lies in the body of sphenoid bone. They may vary in
size and are usually asymmetrical, attributable to the parallel dislocation of the mediating
septum. The relationship of the posterior extension of the sphenoid in relation to the sella
turcica is variable. With the exception of the sinus roof, the other sinus walls are of variable
thickness depending on the degree of pneumatization. The sphenoid sinus is related superiorly
to cavernous sinus, sella turcica and its contents, inferiorly to nasal cavity and posteriorly to
nasal cavity and posterior ethmoidal cells. Posteriorly it is related to middle cranial fossa and
laterally to cavernous sinus and cranial cavity [7].
3.4. Frontal sinus
They are paired structures located between the inner and outer tables of the frontal bone. Each
opening into the anterior part of the corresponding middle nasal meatus of the nose through
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the frontonasal duct. Medially associated with the contralateral frontal sinus, Superiorly, later-
ally and posteriorly with the frontal bone and frontal lobe and Inferiorly with the orbit [7].
4. Etio-pathogenesis
4.1. Etiology
The etiologic factors vary by tumor type and location. Occupational exposures to wood and
leather dust have been strongly associated with sinonasal cancers [7]. The risk of developing
sinonasal cancer also increases with exposure to formaldehyde, in the textile industry and to
nickel/chromiumcompounds [8]. Adenocarcinomas have been associatedwithwooddust, leather
dust, and formaldehyde [9]. The risk is strongest in cases of adenocarcinomas and in sinonasal
malignancies. The impact is present after 40 ormore years since first introduction andpersists after
discontinuation. Squamous cell carcinomas have been linked to arsenic andwelding fumes [10].
High relative risks of sinonasal cancers (SNC) have been observed for specific chemical expo-
sures and occupational settings, including farming, construction, miners, drillers, blasters,
plumbers, machinists, bakers and pastry confectioners, metal industry (chromium and nickel
compounds) [11–14]. In contrast to most head and neck cancers, tobacco smoking does not
seem to have a key role in the development of sinonasal tumors; nevertheless, evidence
suggests that smoking tobacco can increase the risk of SNSCC twofold to threefold [1].
4.2. Pathogenesis
Several studies have established a causal role of exposure to hard wood dust and leather in the
development of sinonasal cancer. Wood dust is a complex mixture of organic and inorganic
components, including genotoxic and carcinogenic factors [15]. Its capacity to induce DNA
damage has been attributed in part to its particulate nature, which induces the generation of
reactive oxygen species in the cells. Several studies have established a causal role of exposure
to hard wood dust and leather in the development of sinonasal cancer, with particular associ-
ation with intestinal-type adenocarcinoma.
Molecular alterations seen in intestinal-type adenocarcinoma (ITAC) mainly focused on TP53,
K-ras and H-ras gene mutations and EGFR or HER2 over-expression. Ras genes were found to
be mutated only in rare cases, with conflicting reports about a possible prognostic role [16].
EGFR and HER2 are over-expressed in about 30% of cases [17]. The rate of TP53 mutations in
intestinal-type adenocarcinoma is about 60% and it is significantly higher than in squamous
cell carcinomas; TP53 mutation rate in ITAC is directly correlated with duration, average and
cumulative level of wood dust exposure [18].
In a study by Chernock et al. (81.8%) were diffusely positive for c-KIT, 27.3% cases were
positive for EGFR, but none of the cases were positive for HER2/neu [19]. In contrast, in a
Challenging Issues on Paranasal Sinuses98
Malignant epithelial tumors
• Squamous cell carcinoma
• Verrucous carcinoma
• Papillary squamous cell carcinoma
• Basaloid squamous cell carcinoma
• Spindle cell carcinoma
• Adenosquamous carcinoma
• Acantholytic squamous cell carcinoma
• Lymphoepithelial carcinoma
• Sinonasal undifferentiated carcinoma
• Adenocarcinoma
• Intestinal-type adenocarcinoma
• Nonintestinal-type adenocarcinoma
• Salivary gland-type carcinomas
• Adenoid cystic carcinoma
• Acinic cell carcinoma
• Mucoepidermoid carcinoma
• Epithelial-myoepithelial carcinoma
• Clear cell carcinoma N.O.S.
• Myoepithelial carcinoma
• Carcinoma ex pleomorphic adenoma
• Polymorphous low-grade adenocarcinoma
• Neuroendocrine tumors
• Typical carcinoid
• Atypical carcinoid
• Small cell carcinoma, neuroendocrine type
Benign epithelial tumors
• Sinonasal papillomas
• lnverted papilloma
• (Schneiderian papilloma, inverted type)
• Oncocytic papilloma
• (Schneiderian papilloma, oncocytic type)
• Exophytic papilloma
• (Schneiderian papilloma, exophytic type)
• Salivary gland-type adenomas
• Pleomorphic adenoma
• Myoepithelioma
• Oncocytoma
Soft tissue tumors
• Malignant tumors
• Fibrosarcoma
• Malignant fibrous histiocytoma
• Leiomyosarcoma
• Rhabdomyosarcoma
• Angiosarcoma
• Malignant peripheral nerve sheath tumor
• Borderline and low malignant potential tumors
• Desmoid-type fibromatosis
• Inflammatory myofibroblastic tumor
• Glomangiopericytoma
• (Sinonasal-type haemangiopericytoma)
• Extrapleural solitary fibrous tumor
• Benign tumors
• Myxoma
• Leiomyoma
• Haemangioma
• Schwannoma
• Neurofibroma
• Meningioma
Tumors of bone and cartilage
• Malignant tumors
• Chondrosarcoma
• Mesenchymal chondrosarcoma
• Osteosarcoma
• Chordoma
• Benign tumors
• Giant cell lesion
• Giant cell tumor
• Chondroma
• Osteoma
• Chondroblastoma
• Chondromyxoid fibroma
• Osteochondroma (exostosis)
• Osteoid osteoma
• Osteoblastoma
• Ameloblastoma
• Nasal chondromesenchymal hamartoma
Haematolymphoid tumors
• Extranodal NK/T cell lymphoma
• Diffuse large B-cell lymphoma
• Extramedullary plasmacytoma
• Extramedullary myeloid sarcoma
• Histiocytic sarcoma
• Langerhans cell histiocytosis
Neuroectodermal
• Ewing sarcoma
• Primitive neuroectodermal tumor
• Olfactory neuroblastoma
• Melanotic neuroectodermal tumor of infancy
• Mucosal malignant melanoma
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study by Takahashi et al., sinonasal squamous cell cancer (SCC) is associated with increase in
number of EGFR and HER2 copies in about 40 and 20% of the cases, respectively, with their
occurrence being mutually exclusive. Expression of these biomarkers is seen in 82% of the
cases, usually indicating a worse outcome [20].
There is increasing evidence that the human papillomavirus (HPV) is associated with a subset
of sinonasal carcinomas. HPV has been detected in about 30% of sinonasal carcinomas [21].
HPV 16 seems to be the most frequent HPV type. The identification of HPV in sinonasal
carcinomas has important clinical implications, because the presence of HPV could be a
prognostic factor associated with a favorable outcome [21].
4.3. Pathological classification
The most-common subtypes of epithelial tumor are sinonasal squamous cell carcinoma, which
predominantly occur in the maxillary sinus and nasal cavity, and intestinal-type adenocarci-
noma (ITAC), which almost exclusively arise in the ethmoid sinus (Table 1) [22].
5. Pattern of spread
The pattern of spread of maxillary sinus cancers varies with the site of origin. Suprastructure
tumors extend into the nasal cavity, ethmoid cells, orbit, pterygopalatine fossa, infratemporal
fossa, and base of skull. Infrastructure tumors often infiltrate the palate, alveolar process,
gingivobuccal sulcus, soft tissue of the cheek, nasal cavity, masseter muscle, pterygopalatine
space, and pterygoid fossa [24].
Lymphatic drainage from the nasal cavity and paranasal sinus occurs in two directions,
anterior, and posterior [25]. The anterior mucosal and vestibular skin drainage is by way of
lymphatic channels traveling to the facial, parotid, or submandibular groups of nodes, then to
the superior deep cervical nodal chain, primarily level II. The posterior lymphatics course
posteriorly to a plexus anterior to the torus tubarius, posterior to the retropharyngeal nodes,
and inferiorly to the posterior and superior deep cervical nodes [26]. Studies have demon-
strated that SCC is associated with a high incidence of nodal metastasis, neck failure and
inferior disease-specific survival rate [27, 28].
Germ cell tumors
• Immature teratoma
• Teratoma with malignant transformation
• Sinonasal yolk sac tumor (endodermal sinus tumor)
• Sinonasal teratocarcinosarcoma
• Mature teratoma
• Dermoid cyst
Secondary tumors
Table 1. Classification of nasal and paranasal sinus tumors (modified by the World Health Organization histological
classification of nasal and paranasal sinus cancer) [23].
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6. Clinical presentation
The majority of maxillary sinus tumors present with nasal fullness, stuffiness, obstruction,
epistaxis, rhinorrhea, pain, paresthesia to tooth mobility, tooth loss, proptosis, diplopia, and
lacrimation [29].
Owing to the nonspecific and the often relatively mild nature of the symptoms at early stages
of disease, sinonasal malignancies have a prolonged diagnostic latency [29].
7. Diagnostic evaluation
Inspection and palpation of the orbits, nasal and oral cavities, and nasopharynx can provide
preliminary determination of tumor extent. Bimanual palpation is important in assessing
contiguous extension of nasal vestibule lesions and in identifying buccinator and submandib-
ular nodal involvement.
For a suspected sinonasal expansile mass, the clinical examination is incomplete without a nasal
endoscopy by flexible and/or rigid endoscopes. Nasal endoscopy allows direct visualization of
the lesion and may help in differentiating an inflammatory polyp from a neoplasm, benign or
malignant. A unilateral expansile mass with an irregular surface, necrotic areas, and contact
bleeding ought to be considered as suspicious and potentially suggestive of malignancy.
Endoscopic evaluation may also allow, especially in those cases not completely filling the nasal
fossa, identification or suggestion of the possible site of origin of the lesion, its local extension
and to assess the presence of satellite lesions. Oral cavity should also be examined to check for
loosening of teeth to rule out involvement of alveolar process of maxilla in cases of maxillary
sinus malignancy or any oro-nasal/oro-antral fistula; maxillary sinus tumours may also pre-
sent as a submucosal swelling at level of the cheek, gingiva-buccal sulcus. A recent history of
an otherwise unexplainable tooth extraction or mobility should also be considered.
Although the incidence of cervical lymph node involvement is relatively low in sinonasal
malignancies, but all cervical lymph node stations must be palpated. The lesions involving the
oral mucosa and/or with aggressive histologic behaviour show high risk of lymphatic spreading
(i.e., sinonasal undifferentiated carcinoma, high-grade olfactory neuroblastoma). In these cases,
clinical evaluation of the neck must be completed by ultrasound so as confirm any neck swelling
and metastasis to neck nodes must be confirmed by fine needle aspiration cytology.
Clinical examination of cranial nerves (from I to VI) should be also performed. Malignancies of
ethmoid sinus or maxillary sinus can present with alteration of eyeball positioning due to
orbital invasion, which can present with proptosis with or without diplopia, due to orbit
compression, intraorbital extension or extrinsic muscle involvement. The infraorbital nerve
(branch of the maxillary division of the trigeminal nerve) can also be affected especially in
lesions extending into the pterygopalatine fossa and/or masticatory space, resulting in sensory
disturbances of the cheek. Involvement of cavernous sinus or orbital apex can lead to visual
disturbances due to optic nerve infiltration.
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In the diagnosis of paranasal sinuses tumors MR imaging is a vital tool in the diagnosis of
these lesions and is used in conjunction with computed tomography to precisely delineate the
extent of neoplasms and involvement of the skull base, the orbits (Figures 2 and 3) [30]. The
involvement of fine bone structures is best evaluated with contrast-enhanced computed
tomography (CECT). CECT provides excellent details about the thin bony paranasal sinuses
walls separating the ethmoid from the anterior skull base and the orbit [31].
7.1. Biopsy
Transnasal biopsy is preferred for tumors arising from or extending into the nasal cavity or
nasopharynx. Some paranasal sinus tumors may be more easily sampled using transoral pro-
cedures or an open Caldwell-Luc approach.
Figure 2. (A) Nonenhanced axial CT scan shows a large, soft tissue mass in the nasal cavity and maxillary sinus, on the
left side. (B) Enhanced axial CT of the lesion shows an inhomogeneously enhancing soft tissue mass.
Figure 3. (A) Axial scan shows T1-weighted image with intermediate signal intensity lobulated mass lesion (white
arrows) in the left maxillary sinus. Obstructed left maxillary sinus have high signal intensity sinonasal secretions (arrow-
heads). (B) Enhanced T1-weighted image shows heterogeneous intense enhancement (black arrows).
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8. Staging
The American Joint Committee on Cancer (AJCC) staging system for the nasal cavity and
paranasal sinuses (8th edition, 2017) is depicted in Tables 2–8 [32] (mucosal melanoma of the
nasal cavity and paranasal sinuses are not included).
Tcategory T criteria for maxillary sinus
TX Primary tumor cannot be assessed
Tis Carcinoma in situ
T1 Tumor limited to maxillary sinus mucosa with no erosion or destruction of bone
T2 Tumor causing bone erosion or destruction including extension into the hard palate and/or middle nasal
meatus, except extension to posterior wall of maxillary sinus and pterygoid plates
T3 Tumor invades any of the following: bone of the posterior wall of maxillary sinus, subcutaneous tissues.
Floor or medial wall of orbit, pterygoid fossa, ethmoid sinuses
T4a Moderately advanced local disease
Tumor invades anterior orbital contents, skin of cheek, pterygoid plates, infratemporal fossa, cribriform plate,
sphenoid or frontal sinuses
T4b Very advanced local disease
Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than
maxillary division of trigeminal nerve (V2), nasopharynx, or clivus
Table 2. T staging for maxillary sinus.
Tcategory T criteria for ethmoid sinus and nasal cavity
TX Primary tumor cannot be assessed
Tis Carcinoma in situ
T1 Tumor restricted to any one subsite, with or without bony invasion
T2 Tumor invading two subsites in a single region or extending to involve an adjacent region within the
nasoethmoidal complex, with or without bony invasion
T3 Tumor extends to invade the medial wall or floor of the orbit, maxillary sinus, palate, or cribriform plate
T4a Moderately advanced local disease
Tumor invades any of the following: anterior orbital contents, skin of nose or cheek, minimal extension to
anterior cranial fossa, pterygoid plates, sphenoid or frontal sinuses
T4b Very advanced local disease
Tumor invades any of the following: orbital apex, dura, brain, middle cranial fossa, cranial nerves other than
(V2), nasopharynx, or clivus
Table 3. T staging for ethmoid sinus and nasal cavity.
N category N criteria
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE()
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N category N criteria
N2 Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and
ENE(); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and
ENE(); or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE
()
N2a Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and
ENE()
N2b Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE()
N2c Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE
()
N3 Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(); or metastasis in any node(s)
with clinically overt ENE(+)
N3a Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE()
N3b Metastasis in any node(s) with clinically overt ENE (ENEC)
Table 4. Clinical regional lymph nodes.
N category N criteria
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE()
N2 Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger
than 3 cm but not larger than 6 cm in greatest dimension and ENE(); or metastases in multiple ipsilateral
lymph nodes, none larger than 6 cm in greatest dimension and ENE (); or in bilateral or contralateral
lymph nodes, none larger than 6 cm in greatest dimension and ENE()
N2a Metastasis in single ipsilateral or contralateral node 3 cm or less in greatest dimension and ENE(+); or a
single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE()
N2b Metastasis in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE()
N2c Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE
()
N3 Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(); or in a single ipsilateral
node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral or bilateral
nodes, any with ENE(+)
N3a Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE()
N3b Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple
ipsilateral, contralateral or bilateral nodes, any with ENE(+)
Table 5. Pathological regional lymph nodes.
M category M criteria
M0 No distant metastasis (no pathologic MO; use clinical M to complete stage group)
M1 Distant metastasis
Table 6. Distant metastasis.
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9. Prognostic factors
Patient-specific factors (primarily prognostic for survival) include age and performance status.
Disease specific factors (primarily prognostic for locoregional control) include location, histol-
ogy, and locoregional extent (reflected in TNM stage), and perineural invasion. Independent of
the treatment type used, the prognosis of patients with sinonasal carcinomas is poor, with an
overall 5-year survival rate of 30–50% [33].The 5-year survival rates depend on disease stage
and drops from 80% in patients with T1 disease to 30% in patients with T4 tumors [34].
Extensive local disease involving the nasopharynx, base of skull, or cavernous sinuses mark-
edly increases surgical morbidity as well as increases local recurrence often within 2 years of
follow up [35].
10. Treatment option overview
Treatment should be individualized based on location and extent of disease, patient perfor-
mance status, stage of tumor, histopathologic subtype of tumor and availability of local
Stage 0 Tis N0 Mo
Stage I T1 N0 M0
Stage II T2 N0 M0
Stage III T3 N0 Mo
T1–3 N1 M0
Stage IVA T4a N0–2 M0
T1–3 N2 M0
Stage IVB T4b Any N M0
Any T N3 M0
Stage IVC Any T Any N M1
Table 7. Anatomic stage/prognostic groups.
GX Grade cannot be assessed
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 Undifferentiated
Table 8. Histologic grade (G).
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expertise; because of the rarity of these tumors, consideration should be given to referring
patients to centers with experience in their management.
Studies have shown that surgery gives the best results. Early infrastructure lesions may be
cured by surgery alone, but, for most other cases, RT is given postoperatively even if margins
are negative. Adjuvant Chemo-radiotherapy should be considered for a positive margin. The
extension of cancer to the skull base, nasopharynx, or sphenoid sinus contraindicates excision
[29, 30, 36].
10.1. Surgery
Surgery can produce excellent control rates for T1 and T2 tumors and is generally the mainstay
of treatment.
However for T2 tumors, radiation therapy along with surgery is recommended. In patients
undergoing radical surgery, it not only removes the bulk of the tumor but also re-establishes
the drainage of involved sinus. It can be further followed by postoperative radiotherapy
depending upon the stage of the tumor. Radical neck dissection or elective neck radiation
therapy is prescribed only for the patients presenting with positive neck nodes. The incidence
of lymph node metastases is generally low (approximately 20% of all cases).
Intracranial extension of tumor (i.e., anterior cranial fossa in cases of involvement of cribriform
plate in ethmoid sinus tumors), cavernous sinus, or the pterygoid process; infiltration of the
mucous membranes of the nasopharynx; or nonresectable lymph node metastases are relative
contraindications to surgery [26, 27].
Maxillary sinus and ethmoid sinus tumors often present as locally advanced disease (large T3
or T4) and are commonly managed with surgery and postoperative radiation therapy. Eth-
moid sinus carcinomas can be treated with radiation alone or with concurrent chemotherapy
to avoid structural or functional deficits [37].
Surgical approaches include fenestrationwith removal of the bulk tumor,which is usually followed
by radiation therapy or block resection of the upper jaw. Surgery generally involves medial
maxillectomy and en bloc ethmoidectomy. A craniofacial approach is required if tumor extends
superiorly to the ethmoid roof or olfactory region. A combined craniofacial approach, including
resection of the floor of the anterior cranial fossa is usedwith success in selected patients [38].
Surgical exploration may be required to determine operability. Destruction of the base of skull
(i.e., anterior cranial fossa), cavernous sinus, or the pterygoid process; infiltration of the
mucous membranes of the nasopharynx; or nonresectable lymph node metastases are relative
contraindications to surgery.
10.2. Chemotherapy
Few studies have investigated the role of neoadjuvant chemotherapy in the management of
advanced cancer of the PNS [39, 40]. Intra-arterial cisplatin in combination with intravenous
paclitaxel and ifosfamide in patients with locally advanced carcinoma of the PNS was studied
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at MD Anderson Cancer Center to determine the efficacy, organ-preservation rate, and safety.
Despite better organ preservation rates, generous toxicity was also reported [41]. Further study
of the role of neoadjuvant chemotherapy in patients with SCC of the PNS is warranted to
determine whether the response (or lack of same) to neoadjuvant chemotherapy can help in
the choice of definitive treatment [42].
Concurrent chemo-radiation therapy can also be used for patients with medical conditions that
preclude surgery if those patients have good performance status. Depending on the patient’s
performance status and renal function, single-agent cisplatin or carboplatin can be used con-
currently with external beam radiation for locally advanced, unresectable squamous cell carci-
noma [43].
10.3. Radiation therapy
RT treatment planning includes the entire maxilla, the adjacent nasal cavity, the ethmoid sinus,
the nasopharynx, and the pterygopalatine fossa. All or part of the orbit is included in patients
with extension into or near the orbit. Target volume definition is aided by the use of treatment
planning CT combined with image-fusion MRI.
When using conventional definitive fractionation, the primary tumor and involved lymph
nodes (i.e., high-risk sites) generally require a total of 66 Gy (2.2 Gy/fraction) to 70 Gy
(2.0 Gy/fraction) [44]. When using hyperfractionation, high-risk sites generally require up to
81.6 Gy (1.2 Gy/fraction) [45]. In contrast, elective irradiation to low-risk and intermediate-risk
sites requires 44 Gy (2.0 Gy/fraction) to 63 Gy (1.6–1.8 Gy/fraction), depending on the esti-
mated level of tumor burden, and on whether 3-D conformal RT or IMRT is used.
For 3-D conformal RT and sequentially planned IMRT, suggest 44–50 Gy (2.0 Gy/fraction). For
concurrent chemoradiation the dose is typically 70–70.2 Gy (1.8–2.0 Gy/fraction) in 5 fractions.
Higher doses of postoperative RT alone (60–66 Gy), or with systemic therapy, are recommended
for the high-risk features of extracapsular disease and/or positive margins (Table 9) [46].
Postoperative RT • T3-T4 primary disease
• Microscopic margins < 5 mm (irrespective of intra-operative revision or additional
postresection sampling of the surgical site)
• >1 additional features at primary:
1. High-grade disease
2. Peri-neural invasion (PNI)
3. Lymph-vascular invasion (LVSI)
• Lymph node involvement at pathology
1. ≥2 lymph nodes
2. Any lymph node > 3 cm (N2+)
3. Level IV-V LN positive
4. Extracapsular extension (ECE)
Preoperative RT • Locally advanced cancer for downstaging of disease
Concurrent
chemoradiotherapy
• Positive (inked) margin
• Extracapsular extension
Table 9. Indications of radiation therapy.
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10.3.1. Simulation and daily localization
The patient is simulated in supine position with head extended and the head and neck are
immobilized. If possible, shoulders should also be immobilized to ensure accurate patient
setup on a daily basis especially when an extended-field IMRT plan is used. To spare the
tongue from high dose nasopharyngeal region, a bite block can be used.
CT scan with IV contrast using 3 mm thickness should be performed from the top of the head
including the brain to the carina. 5 mm thickness can be reconstructed below the clavicle to the
level of the carina.
Image registration and fusion applications with MRI and PET scans should be used to help in
the delineation of target volumes, especially for regions of interest encompassing the gross
tumor, skull base, brainstem, and optic chiasm.
10.4. Complication of treatment
Complications of surgery include failure of the split thickness skin graft to heal, trismus, CSF
leak, meningities, parasinusities and hemorrhage.
The most frequent and significant complications of RT involve the eye [47, 48]. When only a
portion of the ipsilateral eye is irradiated (the medial one third), it is possible to preserve vision
in the majority of patients. When there is extensive disease in the orbit, however, the entire eye
is irradiated to a high dose with almost certain loss of vision. A few patients will experience a
transient CNS syndrome that includes vertigo, headaches, decreased cerebration, and lethargy
[49]. Other rare complications are aseptic meningitis, chronic sinusitis, or serous otitis media.
11. Results of treatment
The management of PNS cancers remains a major challenge in oncology. A major problem in
patients with carcinomas of the PNS is that most tumors are highly advanced at the time point
of diagnosis.
For single-modality therapies, outcome is generally poor. Amendola et al. compared surgery
versus definitive radiation on 39 patients and found no statistically significant differences in
survival at 3 and 5 years, with a 5 year survival rate of 31 and 35% for resection and RT,
respectively. Later, combined modality treatment was considered superior [50]. A number of
reports have demonstrated some improvement in outcome with combined modality therapy.
A report by St. Pierre and Baker based on treatment responses of 61 patients treated with
surgical resection alone, definitive RT or combined treatment, showed a clear benefit for
patients receiving combined surgery [51].
Clinical outcomes of postop patients with carcinomas of the paranasal sinuses and nasal cavity
according to decade of radiation treatment were compared at Memorial Sloan-Kettering Can-
cer Center. In this study, 46% patients were treated by conventional radiotherapy; 35% patients
by three-dimensional conformal radiotherapy; and 18% patients by intensity-modulated
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radiotherapy. The 5-year overall survival rates were 52%, local control rate was 62%, and
disease-free survival was 54%, respectively. There were no significant differences in any of
these parameters with respect to radiotherapy technique. The 5-year overall survival rate for
patients treated in the 1960s, 1970s, 1980s, 1990s, and 2000s was 46, 56, 51, 53, and 49%,
respectively. The observed incidence of severe late toxicity was 53, 45, 39, 28, and 16% among
patients treated in the 1960s, 1970s, 1980s, 1990s, and 2000s, respectively [52].
In the past, the main concern in the radiotherapeutic treatment of PNS tumors was treatment-
related toxicity. The introduction of IMRT now allows application of high doses to complex
target volumes, while the surrounding OARs can be spared and toxicity may be reduced. Over
the last years, IMRT has been implemented widely into the clinical routine. Duthoy et al. com-
pared IMRTwith conventional RT in 39 patients with PNS cancers. In the comparison between
the IMRTand conventional RT groups, no significant differences were found for LC and OS [53].
Dose conformality to the target volume and conformal avoidance of the organs at risk
achieved through IMRT may provide better local control and less optic toxicity compared to
conventional radiotherapy technique. Image-guided radiation therapy (IGRT) has also been
introduced to complement these approaches in ensuring the safe delivery of a highly confor-
mal treatment, by facilitating convenient and frequent imaging of the patient anatomy
throughout the treatment course [54].
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